These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17913384)

  • 1. Centrosome abnormalities in non-small cell lung cancer: correlations with DNA aneuploidy and expression of cell cycle regulatory proteins.
    Jung CK; Jung JH; Lee KY; Kang CS; Kim M; Ko YH; Oh CS
    Pathol Res Pract; 2007; 203(12):839-47. PubMed ID: 17913384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers.
    Geradts J; Fong KM; Zimmerman PV; Maynard R; Minna JD
    Clin Cancer Res; 1999 Apr; 5(4):791-800. PubMed ID: 10213214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity.
    Kinoshita I; Dosaka-Akita H; Mishina T; Akie K; Nishi M; Hiroumi H; Hommura F; Kawakami Y
    Cancer Res; 1996 Dec; 56(24):5557-62. PubMed ID: 8971152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers: analysis in combination with expressions of p16INK4A, pRB, and p53.
    Hirabayashi H; Ohta M; Tanaka H; Sakaguchi M; Fujii Y; Miyoshi S; Matsuda H
    J Surg Oncol; 2002 Dec; 81(4):177-84; discussion 184. PubMed ID: 12451621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of p53, pRB, and p16 in lung tumours: a validation study on tissue microarrays.
    Leversha MA; Fielding P; Watson S; Gosney JR; Field JK
    J Pathol; 2003 Aug; 200(5):610-9. PubMed ID: 12898597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Centrosome abnormalities are frequently observed in non-small-cell lung cancer and are associated with aneuploidy and cyclin E overexpression.
    Koutsami MK; Tsantoulis PK; Kouloukoussa M; Apostolopoulou K; Pateras IS; Spartinou Z; Drougou A; Evangelou K; Kittas C; Bartkova J; Bartek J; Gorgoulis VG
    J Pathol; 2006 Aug; 209(4):512-21. PubMed ID: 16739112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stratification of the biologic aggressiveness of non-small cell lung cancer using DNA flow cytometry and immunohistochemistry for the retinoblastoma protein.
    Otsuka H; Funai S; Tanaka A; Hara S; Shiozaki H
    Lung Cancer; 2004 Sep; 45(3):307-16. PubMed ID: 15301871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
    Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
    Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
    Burke L; Flieder DB; Guinee DG; Brambilla E; Freedman AN; Bennett WP; Jones RT; Borkowski A; Caporaso NA; Fleming M; Trastek V; Pairolero P; Tazelaar H; Midthun D; Jett JR; Liotta LA; Travis WD; Harris CC
    Clin Cancer Res; 2005 Jan; 11(1):232-41. PubMed ID: 15671551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of p16 and lack of pRB in primary small cell lung cancer.
    Yuan J; Knorr J; Altmannsberger M; Goeckenjan G; Ahr A; Scharl A; Strebhardt K
    J Pathol; 1999 Nov; 189(3):358-62. PubMed ID: 10547597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions.
    Parwani AV; Geradts J; Caspers E; Offerhaus GJ; Yeo CJ; Cameron JL; Klimstra DS; Maitra A; Hruban RH; Argani P
    Mod Pathol; 2003 Apr; 16(4):299-308. PubMed ID: 12692194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic heterogeneity studied by immunohistochemistry and aneuploidy in non-small cell lung cancers.
    Pujol JL; Simony J; Laurent JC; Richer G; Mary H; Bousquet J; Godard P; Michel FB
    Cancer Res; 1989 May; 49(10):2797-802. PubMed ID: 2540908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of hydroxyurea-induced centrosome amplification by NORE1A and down-regulation of NORE1A mRNA expression in non-small cell lung carcinoma.
    Shinmura K; Tao H; Nagura K; Goto M; Matsuura S; Mochizuki T; Suzuki K; Tanahashi M; Niwa H; Ogawa H; Sugimura H
    Lung Cancer; 2011 Jan; 71(1):19-27. PubMed ID: 20434789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
    de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
    Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
    Ioachim E
    Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of p53 and MCT-1 overexpression synergistically promote chromosome instability and tumorigenicity.
    Kasiappan R; Shih HJ; Chu KL; Chen WT; Liu HP; Huang SF; Choy CO; Shu CL; Din R; Chu JS; Hsu HL
    Mol Cancer Res; 2009 Apr; 7(4):536-48. PubMed ID: 19372582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
    Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RB growth control evasion in lung cancer.
    Caputi M; Esposito V; Groger AM; De Luca A; Pacilio C; Dekan G; Giordano GG; Baldi F; Wolner E; Giordano A
    Anticancer Res; 1998; 18(4A):2371-4. PubMed ID: 9703881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.